PEMBROKE,
-
A loss portfolio transfer and adverse development agreement (“LPT/ADC”) with
Enstar Group Limited (NASDAQ:ESGR, “Enstar”) pursuant to the previously announced Master Agreement; -
A
$330.7 million commutation agreement (“Commutation”) of certain workers’ compensation loss reserves toAmTrust Financial Services, Inc. (“AmTrust”); and -
Entry into a Post-Termination Endorsement with AmTrust to:
- Enable operation of the LPT/ADC and supporting collateral agreements; and
-
Amend the program loss corridor between Maiden and AmTrust pursuant to the terminated Amended and Restated Quota Share Agreement (the “AmTrust QS Agreement”) between Maiden’s
Bermuda operating company,Maiden Reinsurance Ltd. (“Maiden Bermuda”) andAmTrust International Insurance, Ltd. (“AII”); and
-
Resolution with
Enstar related to balances due under the sale ofMaiden Reinsurance North America, Inc. (“MRNA”), which closed onDecember 27, 2018 , including cancellation of the$25 million excess of loss reinsurance contract between Maiden Bermuda andEnstar on the MRNA loss reserves included in that transaction.
“The transactions completed today represent another significant milestone for Maiden as we continue to stabilize and strengthen the business in the wake of our 2017 and 2018 results,” said
LPT/ADC
All necessary regulatory approvals have been received for the LPT/ADC between
The LPT/ADC was modified from the previously announced limit of
Pursuant to the terms of the LPT/ADC, Maiden Bermuda, Cavello Bay and AmTrust and certain of its affiliated companies have entered into a Master Collateral Agreement (“MCA”) to define and enable the operation of collateral provided under the AmTrust QS Agreement. Under the MCA, Cavello Bay, on behalf of Maiden Bermuda, will provide letters of credit (“LOCs”) to AmTrust in an amount representing Cavello Bay’s obligations under the LPT/ADC. As these LOCs will replace other collateral currently provided directly by Maiden Bermuda to AmTrust, the MCA coordinates the collateral protection that will be provided to AmTrust to ensure that no gaps in collateral funding occur by operation of the LPT/ADC and related MCA.
Settlement of funding will occur no later than
Commutation Agreement
Concurrent with the execution of the LPT/ADC, Maiden Bermuda and AII entered into the Commutation covering the following business reinsured by Maiden Bermuda under the AmTrust QS Agreement (“Commuted Business”):
-
All losses incurred in Accident Year 2017 and Accident Year 2018 under
California workers’ compensation policies issues by AII’s affiliates; and -
All losses incurred in Accident Year 2018 under
New York workers’ compensation policies issues by AII’s affiliates.
The commutation payment from Maiden Bermuda to AII is the sum of the net ceded reserves in the amount of
The Commuted Business does not include any business (i) classified by AII or its affiliates as Specialty Program or Specialty Middle-Market business or (ii) issued by a
Settlement of funding will occur no later than
Maiden received a no objection letter from the BMA regarding the Commutation Agreement.
Post-Termination Endorsement – AmTrust Quota Share Agreements
As a result of entering into both the LPT/ADC and the MCA, certain post-termination endorsements (“Post-Termination Endorsement”) to the AmTrust QS Agreement were required.
The Post-Termination Endorsement enables the operation of both the LPT/ADC and MCA by making provision for certain forms of collateral, including LOCs provided by Cavello Bay on Maiden Bermuda’s behalf. In addition, the Post-Termination Endorsement further defines the permitted use and return of collateral.
The Post-Termination Endorsement also increases the required funding percentage for Maiden Bermuda’s under the collateral arrangements between the parties from 102% to 105% of its obligations, subject to a minimum excess funding requirement of
Finally, as part of the Post-Termination Endorsement, the parties amended the existing loss corridor under the AmTrust QS Agreement to now include a maximum amount of
Resolution with
Maiden completed the sale of MRNA to
About
Forward Looking Statements
This release contains "forward-looking statements" which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on the Company's current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that actual developments will be those anticipated by the Company. Actual results may differ materially from those projected as a result of significant risks and uncertainties, including non-receipt of the expected payments, changes in interest rates, effect of the performance of financial markets on investment income and fair values of investments, developments of claims and the effect on loss reserves, accuracy in projecting loss reserves, the impact of competition and pricing environments, changes in the demand for the Company's products, the effect of general economic conditions and unusual frequency of storm activity, adverse state and federal legislation, regulations and regulatory investigations into industry practices, developments relating to existing agreements, heightened competition, changes in pricing environments, and changes in asset valuations. Additional information about these risks and uncertainties, as well as others that may cause actual results to differ materially from those projected is contained in Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20190805005654/en/
Source:
Sard Verbinnen & Co.
Maiden-SVC@sardverb.com